Caregen Co.Ltd (214370) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caregen Co.Ltd (214370) has a cash flow conversion efficiency ratio of 0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.16 Billion ≈ $2.82 Million USD) by net assets (₩216.88 Billion ≈ $146.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Caregen Co.Ltd market capitalisation for the company's overall valuation and market capitalisation.
Caregen Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Caregen Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Caregen Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caregen Co.Ltd ranked by their cash flow conversion efficiency. Explore Caregen Co.Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Transcom Inc
TW:5222
|
0.028x |
|
Phihong Technology Co Ltd
TW:2457
|
-0.063x |
|
Avalue Technology
TWO:3479
|
0.001x |
|
Pan Malaysia Holdings Bhd
KLSE:1287
|
-0.947x |
|
Prudential plc
LSE:PRU
|
0.073x |
|
Rubellite Energy Inc
TO:RBY
|
0.090x |
|
Guangzhou Improve Med Instrument
SHE:300030
|
0.104x |
|
Huafang Co Ltd
SHG:600448
|
0.148x |
Annual Cash Flow Conversion Efficiency for Caregen Co.Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Caregen Co.Ltd from 2015 to 2024. View Caregen Co.Ltd (214370) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩222.98 Billion ≈ $151.11 Million |
₩13.49 Billion ≈ $9.14 Million |
0.060x | -51.93% |
| 2023-12-31 | ₩227.30 Billion ≈ $154.04 Million |
₩28.60 Billion ≈ $19.38 Million |
0.126x | +198.20% |
| 2022-12-31 | ₩215.98 Billion ≈ $146.37 Million |
₩-27.68 Billion ≈ $-18.76 Million |
-0.128x | -151.82% |
| 2021-12-31 | ₩209.72 Billion ≈ $142.12 Million |
₩51.86 Billion ≈ $35.14 Million |
0.247x | +64.84% |
| 2020-12-31 | ₩205.16 Billion ≈ $139.03 Million |
₩30.78 Billion ≈ $20.86 Million |
0.150x | -53.27% |
| 2019-12-31 | ₩217.01 Billion ≈ $147.06 Million |
₩69.66 Billion ≈ $47.21 Million |
0.321x | +1063.53% |
| 2018-12-31 | ₩204.75 Billion ≈ $138.76 Million |
₩-6.82 Billion ≈ $-4.62 Million |
-0.033x | -116.13% |
| 2017-12-31 | ₩231.83 Billion ≈ $157.11 Million |
₩47.88 Billion ≈ $32.45 Million |
0.207x | +403.39% |
| 2016-12-31 | ₩234.11 Billion ≈ $158.65 Million |
₩-15.94 Billion ≈ $-10.80 Million |
-0.068x | -1180.76% |
| 2015-12-31 | ₩248.87 Billion ≈ $168.66 Million |
₩1.57 Billion ≈ $1.06 Million |
0.006x | -- |
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more